Literature DB >> 7947598

Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.

M Margaglione1, G Di Minno, E Grandone, G Vecchione, E Celentano, G Cappucci, M Grilli, P Simone, S Panico, M Mancini.   

Abstract

We evaluated 106 subjects with and 109 subjects without a history of ischemic stroke. All were attending a metabolic ward. The two groups were compared for major risk factors for ischemic events. A positive family history for ischemic complications of atherosclerosis was more common in subjects with a history of stroke than in those without; moreover, plasma levels of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (TPA) were higher in patients with documented previous events. A strong positive significant correlation was found between TPA and PAI-1 levels, and an interaction between age and TPA was observed when the sample was stratified according to ages being above or below 70 years. When the patient population was analyzed according to the number of ischemic events, it was found that 62 of the 106 subjects with a history of stroke had experienced more than one ischemic event. Under these conditions, the levels of TPA and PAI-1 still correlated with the occurrence of previous ischemic episodes. As in the whole patient sample, TPA was the strongest discriminator. We conclude that in subjects attending a metabolic ward, TPA and PAI-1 levels consistently help identify subjects with a history of cerebral ischemic episodes and that TPA is the strongest discriminator.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947598     DOI: 10.1161/01.atv.14.11.1741

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  12 in total

1.  Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats.

Authors:  Z G Zhang; M Chopp; A Goussev; D Lu; D Morris; W Tsang; C Powers; K L Ho
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

2.  Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

3.  The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.

Authors:  Ayman A El Menyar; O M Altamimi; Mohamed M Gomaa; Zainab Fawzy; M O Abdel Rahman; Abdulbari Bener
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

4.  Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

5.  Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Authors:  Antonio Barbato; Roberto Iacone; Giovanni Tarantino; Ornella Russo; Paolo Sorrentino; Sonia Avallone; Ferruccio Galletti; Eduardo Farinaro; Elisabetta Della Valle; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-04-07       Impact factor: 3.397

6.  Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.

Authors:  Machteld Sillen; Stephen D Weeks; Xiaohua Zhou; Andrey A Komissarov; Galina Florova; Steven Idell; Sergei V Strelkov; Paul J Declerck
Journal:  J Thromb Haemost       Date:  2020-02-20       Impact factor: 5.824

7.  Epistatic interactions in genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.

Authors:  Nadia M Penrod; Kwabena A Poku; Douglas E Vaughan; Douglas E Vaughn; Folkert W Asselbergs; Nancy J Brown; Jason H Moore; Scott M Williams
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

8.  Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.

Authors:  C Nafría; I Fernández-Cadenas; M Mendioroz; S Domingues-Montanari; M Hernández-Guillamón; J Fernández-Morales; A Del Río-Espínola; D Giralt; L Deu; P Delgado; A Rosell; J Montaner
Journal:  Stroke Res Treat       Date:  2011-06-09

9.  A comparative pharmacogenomic analysis of three classic TCM prescriptions for coronary heart disease based on molecular network modeling.

Authors:  Ying-Ying Zhang; Zi-de Zhao; Peng-Yun Kong; Lin Gao; Ya-Nan Yu; Jun Liu; Peng-Qian Wang; Bing Li; Xiao-Xu Zhang; Li-Qiang Yang; Zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2020-02-12       Impact factor: 6.150

10.  Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity.

Authors:  Machteld Sillen; Stephen D Weeks; Sergei V Strelkov; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2020-08-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.